TyraTech deal gets a big tick (Novartis) - 500 Beiträge pro Seite
eröffnet am 22.08.13 15:58:34 von
neuester Beitrag 17.10.14 12:19:10 von
neuester Beitrag 17.10.14 12:19:10 von
Beiträge: 21
ID: 1.185.071
ID: 1.185.071
Aufrufe heute: 0
Gesamt: 1.148
Gesamt: 1.148
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| 19.06.11, 13:50 | 159 | |
| gestern 12:46 | 109 | |
| 02.07.09, 11:22 | 87 | |
| gestern 21:35 | 82 | |
| 24.01.14, 16:47 | 69 | |
| vor 1 Stunde | 67 | |
| gestern 23:06 | 54 | |
| 21.02.13, 13:43 | 42 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 17.749,00 | -0,14 | 172 | |||
| 2. | 2. | 149,93 | -3,55 | 121 | |||
| 3. | 3. | 7,0000 | -5,41 | 78 | |||
| 4. | 7. | 6,7290 | +2,08 | 58 | |||
| 5. | 6. | 6,6100 | +7,48 | 57 | |||
| 6. | 4. | 2.375,95 | -0,11 | 55 | |||
| 7. | 5. | 0,1845 | -8,21 | 54 | |||
| 8. | 8. | 3,7400 | +3,82 | 51 |
Feedback
Additional Information
Market: AIM
Sector: Chemicals
EPIC: TYR
Latest Price: 5.63p (0,00%)
52-week High: 6.50p
52-week Low: 2.75p
Market Cap: 9.50M
Homepage: http://www.tyratech.com/
Pro Active Investor Profil:
http://www.proactiveinvestors.co.uk/LON:TYR/TyraTech-Inc/
TyraTech deal gets a big tick
http://www.proactiveinvestors.co.uk/companies/news/60297/tyr…
By John Harrington August 22 2013
Small company. Big world. The challenge for the former is to sell to large parts of the latter.
TyraTech (LON:TYR), the insecticide specialist, appears to have cracked this problem by signing a distribution deal, announced on August 14, with the animal health care arm of the Swiss pharmaceutical giant Novartis
The global distribution partnership with Novartis Animal Health, the worldwide leader in biocide products, also represents a massive endorsement of the biocide products of TyraTech.
It is the start of a potentially strong partnership that could galvanise the prospects of the £10mln valued AIM-listed company.
The deal will see TyraTech products rebadged with the Novartis brand, which means the might of the Novartis marketing machine will be behind the products.
“We have Novartis brand recognition, brand trust, and we have Novartis doing the marketing and technical support to farmers,” TyraTech chief executive Bruno Jactel told Proactive Investors, adding that TyraTech would “greatly benefit” from having Novartis in its corner.
Jactel believes the deal is the best and most efficient way for TyraTech to get its products to market.
“Going with Novartis offers several benefits to TyraTech.
“One, is that they are the leader in their market, so they can provide the technical support necessary to introduce our new technology in markets where we are not present.
“Second, they have worldwide access. They are present in more than 40 countries with their own subsidiaries, and they have distributors in the rest of the countries, so it allows us to get almost worldwide access pretty quickly,” Jactel explained.
Novartis Animal Health has around 2,900 employees and global annual sales of more than US$1bn. As Jactel indicated, it is a global leader in biocide products – chiefly ones used in livestock and production animal premises to protect against infectious diseases from insects and pests.
After giving TyraTech’s biocide range a good checking over, Novartis declared itself happy to put its own name on the product labels. That sort of endorsement could open a lot of doors to TyraTech should it seek to seal similar deals with other global players.
On the other hand, if the relationship with Novartis develops as TyraTech hopes, the company would have no incentive to go with anyone else.
“They are the leader in the market,” Jactel reiterated.
“Obviously, we are moving towards a very strong and positive relationship,” he added. There is the possibility of Novartis Animal Health signing agreements for other parts of TyraTech’s portfolio. For now, however, both parties are keeping their options open.
“We have a lot of flexibility in that [respect]. If the relationship goes well with Novartis, we have a partner that would allow us to put [on the market], quickly and efficiently, our other animal health products that we have in the pipeline.
“Second, it also demonstrates that our technology is very beneficial and very interesting for a multi-national company, and that we have the possibility to deal with multi-nationals. That is a testament to the quality of our technology as well as the quality of our products, which have been extensively tested by Novartis.
"They (Novartis) concluded that these products are very good, and they are keen to distribute them under their brand, so, again, it really shows how far TyraTech has gone into developing innovation, strong technology, and products that make an impact in the market.”
What Novartis will get from TyraTech is a number of biocide products developed using TyraTech’s breakthrough technology, to tackle the main banes of livestock farmers: flies and cockroaches.
Tests indicate these TyraTech products are at least as good, if not better, as existing synthetic chemical pesticides at their primary job of exterminating pests. That the products are friendlier to the environment is a significant bonus that should not be overlooked in these environmentally conscious times.
It is often suggested that the only creatures likely to survive a nuclear holocaust are cockroaches (and possibly lawyers), so the pests are renowned for being resistant to extermination attempts, and their proliferation represents a serious problem to food production facilities.
As such, the market opportunity for TyraTech’s products in just this one area is enormous.
Moving on from creepy-crawlies to flying insects, the common house fly alone is responsible for a distressingly large amount of damage to livestock across the world. Meanwhile, the horn fly causes “billions of dollars of damage and loss to the cattle industry each year”, according to the Texas A&M University, while research by the University of Nebraska into the economic damage caused by stable flies indicates “weight gain depressions of 0.48 pounds per day and milk production decreases of 30 per cent to 40 per cent have been recorded” in cattle blighted by the pests.
With the world’s population growing exponentially, and with it the demand for food, there is little doubt that TyraTech is in the right business and following this month’s deal, it has the right partner.
Market: AIM
Sector: Chemicals
EPIC: TYR
Latest Price: 5.63p (0,00%)
52-week High: 6.50p
52-week Low: 2.75p
Market Cap: 9.50M
Homepage: http://www.tyratech.com/
Pro Active Investor Profil:
http://www.proactiveinvestors.co.uk/LON:TYR/TyraTech-Inc/
TyraTech deal gets a big tick
http://www.proactiveinvestors.co.uk/companies/news/60297/tyr…
By John Harrington August 22 2013
Small company. Big world. The challenge for the former is to sell to large parts of the latter.
TyraTech (LON:TYR), the insecticide specialist, appears to have cracked this problem by signing a distribution deal, announced on August 14, with the animal health care arm of the Swiss pharmaceutical giant Novartis
The global distribution partnership with Novartis Animal Health, the worldwide leader in biocide products, also represents a massive endorsement of the biocide products of TyraTech.
It is the start of a potentially strong partnership that could galvanise the prospects of the £10mln valued AIM-listed company.
The deal will see TyraTech products rebadged with the Novartis brand, which means the might of the Novartis marketing machine will be behind the products.
“We have Novartis brand recognition, brand trust, and we have Novartis doing the marketing and technical support to farmers,” TyraTech chief executive Bruno Jactel told Proactive Investors, adding that TyraTech would “greatly benefit” from having Novartis in its corner.
Jactel believes the deal is the best and most efficient way for TyraTech to get its products to market.
“Going with Novartis offers several benefits to TyraTech.
“One, is that they are the leader in their market, so they can provide the technical support necessary to introduce our new technology in markets where we are not present.
“Second, they have worldwide access. They are present in more than 40 countries with their own subsidiaries, and they have distributors in the rest of the countries, so it allows us to get almost worldwide access pretty quickly,” Jactel explained.
Novartis Animal Health has around 2,900 employees and global annual sales of more than US$1bn. As Jactel indicated, it is a global leader in biocide products – chiefly ones used in livestock and production animal premises to protect against infectious diseases from insects and pests.
After giving TyraTech’s biocide range a good checking over, Novartis declared itself happy to put its own name on the product labels. That sort of endorsement could open a lot of doors to TyraTech should it seek to seal similar deals with other global players.
On the other hand, if the relationship with Novartis develops as TyraTech hopes, the company would have no incentive to go with anyone else.
“They are the leader in the market,” Jactel reiterated.
“Obviously, we are moving towards a very strong and positive relationship,” he added. There is the possibility of Novartis Animal Health signing agreements for other parts of TyraTech’s portfolio. For now, however, both parties are keeping their options open.
“We have a lot of flexibility in that [respect]. If the relationship goes well with Novartis, we have a partner that would allow us to put [on the market], quickly and efficiently, our other animal health products that we have in the pipeline.
“Second, it also demonstrates that our technology is very beneficial and very interesting for a multi-national company, and that we have the possibility to deal with multi-nationals. That is a testament to the quality of our technology as well as the quality of our products, which have been extensively tested by Novartis.
"They (Novartis) concluded that these products are very good, and they are keen to distribute them under their brand, so, again, it really shows how far TyraTech has gone into developing innovation, strong technology, and products that make an impact in the market.”
What Novartis will get from TyraTech is a number of biocide products developed using TyraTech’s breakthrough technology, to tackle the main banes of livestock farmers: flies and cockroaches.
Tests indicate these TyraTech products are at least as good, if not better, as existing synthetic chemical pesticides at their primary job of exterminating pests. That the products are friendlier to the environment is a significant bonus that should not be overlooked in these environmentally conscious times.
It is often suggested that the only creatures likely to survive a nuclear holocaust are cockroaches (and possibly lawyers), so the pests are renowned for being resistant to extermination attempts, and their proliferation represents a serious problem to food production facilities.
As such, the market opportunity for TyraTech’s products in just this one area is enormous.
Moving on from creepy-crawlies to flying insects, the common house fly alone is responsible for a distressingly large amount of damage to livestock across the world. Meanwhile, the horn fly causes “billions of dollars of damage and loss to the cattle industry each year”, according to the Texas A&M University, while research by the University of Nebraska into the economic damage caused by stable flies indicates “weight gain depressions of 0.48 pounds per day and milk production decreases of 30 per cent to 40 per cent have been recorded” in cattle blighted by the pests.
With the world’s population growing exponentially, and with it the demand for food, there is little doubt that TyraTech is in the right business and following this month’s deal, it has the right partner.
Antwort auf Beitrag Nr.: 45.304.085 von Jon_Schnee am 22.08.13 15:58:34Story:
TyraTech placing will speed up and expand the commercialisation of the business
http://www.youtube.com/watch?v=3c8C8b7SaAA
TyraTech placing will speed up and expand the commercialisation of the business
http://www.youtube.com/watch?v=3c8C8b7SaAA
Technologie /Produkte
siehe Link:
http://www.tyratech.com/archive/presentations/corporate_pres…
Auszug aus Presentation:
TyraTech’s unique product benefits
Efficacy
As efficacious as (or superior to) existing synthetic chemical pesticides
Effective against resistant pests
Scientifically proven
Safety
No synthetic chemical pesticides
Superior level of safety for the environment, no residues
No risk of food chain contamination
Safely used in the presence of animals or children
Safe for both topical and oral usage
No restrictions on re‐use
Cosmetics & Convenience
Highly convenient: no need for professional application
Excellent cosmetics and aesthetics (natural fragrances, non‐sticky)
siehe Link:
http://www.tyratech.com/archive/presentations/corporate_pres…
Auszug aus Presentation:
TyraTech’s unique product benefits
Efficacy
As efficacious as (or superior to) existing synthetic chemical pesticides
Effective against resistant pests
Scientifically proven
Safety
No synthetic chemical pesticides
Superior level of safety for the environment, no residues
No risk of food chain contamination
Safely used in the presence of animals or children
Safe for both topical and oral usage
No restrictions on re‐use
Cosmetics & Convenience
Highly convenient: no need for professional application
Excellent cosmetics and aesthetics (natural fragrances, non‐sticky)
Antwort auf Beitrag Nr.: 45.304.085 von Jon_Schnee am 22.08.13 15:58:34Und noch was fürs "Auge" Na ja, lecker siehts ja nicht aus 
Aber man bekommt mal ein Eindruck was sie so machen:
http://terminixproducts.com/products/
Aber man bekommt mal ein Eindruck was sie so machen:
http://terminixproducts.com/products/
2012 - Annual Report
http://www.tyratech.com/archive/results/ar2012.pdf
http://www.tyratech.com/archive/results/ar2012.pdf
Trading Spotlight
Zitat von Jon_Schnee: 2012 - Annual Report
http://www.tyratech.com/archive/results/ar2012.pdf
u.a.:
Total revenues 3,572,659
Total cost and expenses 6,051,993
Loss from operations (2,940,738)
Net loss $(2,935,664) $
Zitat von Jon_Schnee: TyraTech deal gets a big tick (Novartis)
"Grundsätzlich" schon interessant, aber die verbrennen (schon seit Jahren!)einen Haufen Kohle. Und wenn Du jetzt meinst "aber jetzt haben sie ein Abkommen mit Novartis" -Klar, nur an (größeren) (Vertriebs)Partnern hat es Ihnen davor auch schon nicht gemangelt.
Ich würde meinen wenn, dann muss man hier die operative Entwicklung sehr genau im Blick behalten. Und dass Du mich nicht falsch verstehst -das sind prinzipiell genau die Art Firmen, die ich spannend finde.
Gruß
P.
Antwort auf Beitrag Nr.: 45.306.001 von Popeye82 am 22.08.13 20:00:43Hallo Popeeye
Ich stimme Dir zu.
TyraTech hat die Kommerzialisierung alleine nicht gerade erfolgreich aufgezogen und wird es alleine nach meiner Meinung nicht schaffen.
Die Frage ist wieso? Schlechte Produkte oder kein Plan von Verkauf & Marketing?
Was mich positiv stimmt das Novartis Produkte unter eigenen Brands vermarkten möchte. Hier sehe die Change auf Erfolg.
Ansosten wird TyraTech ein Rohrkrepierer.
"They (Novartis) concluded that these products are very good, and they are keen to distribute them under their brand, so, again, it really shows how far TyraTech has gone into developing innovation, strong technology, and products that make an impact in the market.”
Ich stimme Dir zu.
TyraTech hat die Kommerzialisierung alleine nicht gerade erfolgreich aufgezogen und wird es alleine nach meiner Meinung nicht schaffen.
Die Frage ist wieso? Schlechte Produkte oder kein Plan von Verkauf & Marketing?
Was mich positiv stimmt das Novartis Produkte unter eigenen Brands vermarkten möchte. Hier sehe die Change auf Erfolg.
Ansosten wird TyraTech ein Rohrkrepierer.
"They (Novartis) concluded that these products are very good, and they are keen to distribute them under their brand, so, again, it really shows how far TyraTech has gone into developing innovation, strong technology, and products that make an impact in the market.”
Antwort auf Beitrag Nr.: 45.306.001 von Popeye82 am 22.08.13 20:00:43ps. der Kurs bröckelt wieder ab. TyraTech ist für mich ein Watch List Wert. Denke hier sieht man noch tiefere Kurse... Bei 4-5p wird's für mich interessant.
BIG PICTURE -Tyratech sees Walmart deal as US springboard
http://www.proactiveinvestors.co.uk/companies/news/64879/big…
By Philip Whiterow
Investors celebrated TyraTech’s (LON:TYR) announcement that its new natural head lice treatment, Vamousse, was to be sold in Walmart
stores from the end of March.
Bruno Jactel, TyraTech’s chief executive, said it was the company’s most important milestone to date and it is easy to see why he is optimistic.
Walmart is the US’s largest retailer with 4,000 stores as well as a huge online operation and selling a product through a distribution chain of this size clearly has major implications for a company currently valued at under £6mln.
Of course, because a product is on the shop shelves doesn’t mean people will buy it, but TyraTech is confident Vamousse has enough significant advantages over the competition to make a quick and meaningful impact.
While not a topic for polite conversation, anyone with children of school age will be very aware head lice are a problem as prevalent as ever.
In the US that means up to 12mln infestations in children each year and a market worth US$150mln.
Tyratech says Vamousse kills 100% of head lice and nits in 15 minutes, a clear benefit over existing, longstanding treatments where resistance is now becoming a significant problem.
Technically, especially in its once only application, it is much more sophisticated while there are not the toxicity issues associated with the pesticides used in competitor products.
Jactel expects these plusses to lead to strong penetration in the US market, but perhaps as importantly it will raise TyraTech’s profile among other retailers.
Vamousse will be badged as a TyraTech product, unlike the deal it signed recently with Novartis for its range of animal health insecticides that will be marketed under the Swiss pharma giant’s name.
While that tie-up with Novartis was a big one in its own right, with the first products set for launch this year, direct deals generate better margins and should build more long term value.
That’s important for TyraTech as Vamousse is just one of a number of natural oil-based products lined up for the US market.
These include a preventative shampoo for head lice to follow Vamousse that it hopes will transform the market by switching the emphasis to prevention rather than treatment.
Another new product is a natural oil-based repellent for mosquitoes and ticks. The personal repellent market is worth about US$200mln and dominated by products based on DEET, a pesticide developed by the Americans for the Vietnam War.
Tyratech believes its product is far superior and is targeting a launch to catch the peak of the US mosquito season this year between May and September.
In addition, if Vamousse proves a success, Walmart may roll it out across its global stores network, which could include its subsidiary Asda. The product is already registered in the UK.
Clearly much is resting on how well Vamousse is received when it makes its appearance, but N+1 Singer has pencilled in a jump to sales of US$6mln for 2014 rising to US$8.6mln in 2015.
These revenues will be predicated it said, on the treatment gaining a significant market share in the US and more modest success in Europe.
Jactel added that the Walmart deal had reinforced the company's confidence it would meet market expectations for revenues in 2014.
Shares were up 3% today at 5.15p.
http://www.proactiveinvestors.co.uk/companies/news/64879/big…
By Philip Whiterow
Investors celebrated TyraTech’s (LON:TYR) announcement that its new natural head lice treatment, Vamousse, was to be sold in Walmart
stores from the end of March.Bruno Jactel, TyraTech’s chief executive, said it was the company’s most important milestone to date and it is easy to see why he is optimistic.
Walmart is the US’s largest retailer with 4,000 stores as well as a huge online operation and selling a product through a distribution chain of this size clearly has major implications for a company currently valued at under £6mln.
Of course, because a product is on the shop shelves doesn’t mean people will buy it, but TyraTech is confident Vamousse has enough significant advantages over the competition to make a quick and meaningful impact.
While not a topic for polite conversation, anyone with children of school age will be very aware head lice are a problem as prevalent as ever.
In the US that means up to 12mln infestations in children each year and a market worth US$150mln.
Tyratech says Vamousse kills 100% of head lice and nits in 15 minutes, a clear benefit over existing, longstanding treatments where resistance is now becoming a significant problem.
Technically, especially in its once only application, it is much more sophisticated while there are not the toxicity issues associated with the pesticides used in competitor products.
Jactel expects these plusses to lead to strong penetration in the US market, but perhaps as importantly it will raise TyraTech’s profile among other retailers.
Vamousse will be badged as a TyraTech product, unlike the deal it signed recently with Novartis for its range of animal health insecticides that will be marketed under the Swiss pharma giant’s name.
While that tie-up with Novartis was a big one in its own right, with the first products set for launch this year, direct deals generate better margins and should build more long term value.
That’s important for TyraTech as Vamousse is just one of a number of natural oil-based products lined up for the US market.
These include a preventative shampoo for head lice to follow Vamousse that it hopes will transform the market by switching the emphasis to prevention rather than treatment.
Another new product is a natural oil-based repellent for mosquitoes and ticks. The personal repellent market is worth about US$200mln and dominated by products based on DEET, a pesticide developed by the Americans for the Vietnam War.
Tyratech believes its product is far superior and is targeting a launch to catch the peak of the US mosquito season this year between May and September.
In addition, if Vamousse proves a success, Walmart may roll it out across its global stores network, which could include its subsidiary Asda. The product is already registered in the UK.
Clearly much is resting on how well Vamousse is received when it makes its appearance, but N+1 Singer has pencilled in a jump to sales of US$6mln for 2014 rising to US$8.6mln in 2015.
These revenues will be predicated it said, on the treatment gaining a significant market share in the US and more modest success in Europe.
Jactel added that the Walmart deal had reinforced the company's confidence it would meet market expectations for revenues in 2014.
Shares were up 3% today at 5.15p.
UPDATE - TyraTech hails US launch of Novartis-backed livestock product
http://www.proactiveinvestors.co.uk/companies/news/68059/upd…
The milestones are coming thick and fast for TyraTech (LON:TYR), the specialist in nature-derived insect and parasite control products.
This morning the group announced the US launch of Natunex, a new line of non-toxic biocides that provides highly effective and fast insect control in livestock.
The product will be distributed by Novartis Animal Health in the States, and taps both companies into a market predicted to be worth US$1bn by 2016.
Chief executive Bruno Jactel said: "TyraTech is excited about delivering the Natunex product line, which addresses the increased demand from livestock producers for efficacious, safe and more practical solutions to control insects and parasites.
“The partnership with Novartis Animal Health will make Natunex immediately available across Novartis' network of US livestock producers, with a global roll-out forthcoming.
“In addition, this relationship demonstrates the effectiveness and quality of TyraTech's technology and products. Natunex represents a significant step forward in non-toxic, environmentally friendly and highly effective pest control."
The announcement reveals it is business as usual for the Swiss drugs giant, which is in the formative stages of a sale of its animal health unit to Eli Lilly.
It is just one of a series of announcements that show TyraTech is turning its early promise into commercial reality.
At the end of last month its Vamousse treatment for head lice went on sale in 4,000 Wal-Mart stores.
Vamousse and Natunex are just two of a number of natural oil-based products lined up for the US market. These include a preventative shampoo for head lice to follow Vamousse that it hopes will transform the market by switching the emphasis to prevention rather than treatment.
Another new product is a natural oil-based repellent for mosquitoes and ticks. The personal repellent market is worth about US$200mln and dominated by products based on DEET, a pesticide developed by the Americans for the Vietnam War.
The shares, up 130% in the year to date, added a further 1% to stand at 11.6p each at noon.
http://www.proactiveinvestors.co.uk/companies/news/68059/upd…
The milestones are coming thick and fast for TyraTech (LON:TYR), the specialist in nature-derived insect and parasite control products.
This morning the group announced the US launch of Natunex, a new line of non-toxic biocides that provides highly effective and fast insect control in livestock.
The product will be distributed by Novartis Animal Health in the States, and taps both companies into a market predicted to be worth US$1bn by 2016.
Chief executive Bruno Jactel said: "TyraTech is excited about delivering the Natunex product line, which addresses the increased demand from livestock producers for efficacious, safe and more practical solutions to control insects and parasites.
“The partnership with Novartis Animal Health will make Natunex immediately available across Novartis' network of US livestock producers, with a global roll-out forthcoming.
“In addition, this relationship demonstrates the effectiveness and quality of TyraTech's technology and products. Natunex represents a significant step forward in non-toxic, environmentally friendly and highly effective pest control."
The announcement reveals it is business as usual for the Swiss drugs giant, which is in the formative stages of a sale of its animal health unit to Eli Lilly.
It is just one of a series of announcements that show TyraTech is turning its early promise into commercial reality.
At the end of last month its Vamousse treatment for head lice went on sale in 4,000 Wal-Mart stores.
Vamousse and Natunex are just two of a number of natural oil-based products lined up for the US market. These include a preventative shampoo for head lice to follow Vamousse that it hopes will transform the market by switching the emphasis to prevention rather than treatment.
Another new product is a natural oil-based repellent for mosquitoes and ticks. The personal repellent market is worth about US$200mln and dominated by products based on DEET, a pesticide developed by the Americans for the Vietnam War.
The shares, up 130% in the year to date, added a further 1% to stand at 11.6p each at noon.
TyraTech granted two new US patents
By Jamie Nimmo
April 24 2014, 7:26am
http://www.proactiveinvestors.co.uk/companies/news/67869/tyr…
Insecticide specialist TyraTech (LON:TYR) has been granted two new patents for its pest control compositions by the US authorities.
The first patent covers a range of current and pipeline animal health products, including those that will be sold by Novartis Animal Health US for the control of flies, cockroaches and other insects in production animal facilities.
The patent, which has a 20-year term, also covers products sold into professional pest control by Envance Technologies, TyraTech’s joint venture with AMVAC Chemical Corporation.
The second patent covers the company’s Extend technology, which aims at increasing efficacy while reducing the environmental effects of synthetic pesticides.
It supports a number of TyraTech’s animal health pipeline products, as well as pipeline products from Envance Technologies.
The group now has 21 patents, with another 50 pending.
Chief executive Bruno Jactel said: “These new patents are a testimony to the quality and innovation behind TyraTech's technology and products. More importantly they will provide protection for TyraTech's products that are already in the market and for products that TyraTech is currently developing.
“Our research and development teams are continually working to develop new products and formulations that are patentable with the objective of strengthening our growth platform.”
By Jamie Nimmo
April 24 2014, 7:26am
http://www.proactiveinvestors.co.uk/companies/news/67869/tyr…
Insecticide specialist TyraTech (LON:TYR) has been granted two new patents for its pest control compositions by the US authorities.
The first patent covers a range of current and pipeline animal health products, including those that will be sold by Novartis Animal Health US for the control of flies, cockroaches and other insects in production animal facilities.
The patent, which has a 20-year term, also covers products sold into professional pest control by Envance Technologies, TyraTech’s joint venture with AMVAC Chemical Corporation.
The second patent covers the company’s Extend technology, which aims at increasing efficacy while reducing the environmental effects of synthetic pesticides.
It supports a number of TyraTech’s animal health pipeline products, as well as pipeline products from Envance Technologies.
The group now has 21 patents, with another 50 pending.
Chief executive Bruno Jactel said: “These new patents are a testimony to the quality and innovation behind TyraTech's technology and products. More importantly they will provide protection for TyraTech's products that are already in the market and for products that TyraTech is currently developing.
“Our research and development teams are continually working to develop new products and formulations that are patentable with the objective of strengthening our growth platform.”
TyraTech passing the milestones
By Ian Lyall May 19 2014
http://www.proactiveinvestors.co.uk/companies/news/68639/tyr…
TyraTech (LON:TYR) chief executive (CEO) Bruno Jactel told investors 2014 would be about delivery. Five-and-a-half months into the year, the company has made significant progress commercialising its range of nature-derived and safe insecticides.
Today’s announcement is just the latest in a series of significant milestones with the group revealing Amazon.com and Drugstore.com have agreed to take its head lice treatments and prevention products (click here for our earlier story).
Vamousse, its safe, natural, but 100% effective treatment for head lice, is already available on Amazon.com while Drugstore.com will start carrying the product line in the next few weeks.
It is the second important announcement from TyraTech in the last few weeks. On April 30 TyraTech revealed Novartis had launched Natunex, a new line of non-toxic biocides that provides highly effective and fast insect control in and around livestock production facilities.
The products will be distributed by Novartis Animal Health in the States, and taps both companies into a worldwide market predicted to be worth US$1bn by 2016.
Meanwhile, much excitement surrounds Vamousse, which as well as being available online has also been stocked in 4,100 Wal-Mart stores in the US since the beginning of April.
“Everything is going to plan,” CEO Jactel told Proactive Investors.
“We are now in all the Wal-Mart stores nationwide and our product seems to be selling well.
“Having said that, it is too early to draw any conclusions and it is the low part of the season.
“The logistic part seems to be working well. We are top of the class as far as quality of delivery is concerned.
“We have put in a very good system.”
The addition of Amazon and Drugstore adds two new routes to market, and, crucially, they are expected be a great launch pad for TyraTech’s head lice preventative shampoo.
“Head lice treatment products are usually an emergency buy, as people want to treat immediately, but the online distribution is always convenient and is a great way to go for the preventative shampoo. We now have two of the three biggest websites for over-the-counter-drugs in the USA.
“Our Vamousse treatment is available at Wal-Mart stores and online via Amazon.com and Drugstore.com, giving consumers several convenient ways to buy the product,”
The TyraTech boss also confirmed its commercial team will approach the big pharmacy chains when they review their product lines over the summer.
He also expects Vamousse to gain traction with the distributors that supply the 25,000 or so independent pharmacies that make up part of the pharmacy market.
“We are keeping the momentum going and widening our distribution network in the USA,” Jactel told Proactive.
“We are attracting new distributors all the time. It is a very exciting time.”
By Ian Lyall May 19 2014
http://www.proactiveinvestors.co.uk/companies/news/68639/tyr…
TyraTech (LON:TYR) chief executive (CEO) Bruno Jactel told investors 2014 would be about delivery. Five-and-a-half months into the year, the company has made significant progress commercialising its range of nature-derived and safe insecticides.
Today’s announcement is just the latest in a series of significant milestones with the group revealing Amazon.com and Drugstore.com have agreed to take its head lice treatments and prevention products (click here for our earlier story).
Vamousse, its safe, natural, but 100% effective treatment for head lice, is already available on Amazon.com while Drugstore.com will start carrying the product line in the next few weeks.
It is the second important announcement from TyraTech in the last few weeks. On April 30 TyraTech revealed Novartis had launched Natunex, a new line of non-toxic biocides that provides highly effective and fast insect control in and around livestock production facilities.
The products will be distributed by Novartis Animal Health in the States, and taps both companies into a worldwide market predicted to be worth US$1bn by 2016.
Meanwhile, much excitement surrounds Vamousse, which as well as being available online has also been stocked in 4,100 Wal-Mart stores in the US since the beginning of April.
“Everything is going to plan,” CEO Jactel told Proactive Investors.
“We are now in all the Wal-Mart stores nationwide and our product seems to be selling well.
“Having said that, it is too early to draw any conclusions and it is the low part of the season.
“The logistic part seems to be working well. We are top of the class as far as quality of delivery is concerned.
“We have put in a very good system.”
The addition of Amazon and Drugstore adds two new routes to market, and, crucially, they are expected be a great launch pad for TyraTech’s head lice preventative shampoo.
“Head lice treatment products are usually an emergency buy, as people want to treat immediately, but the online distribution is always convenient and is a great way to go for the preventative shampoo. We now have two of the three biggest websites for over-the-counter-drugs in the USA.
“Our Vamousse treatment is available at Wal-Mart stores and online via Amazon.com and Drugstore.com, giving consumers several convenient ways to buy the product,”
The TyraTech boss also confirmed its commercial team will approach the big pharmacy chains when they review their product lines over the summer.
He also expects Vamousse to gain traction with the distributors that supply the 25,000 or so independent pharmacies that make up part of the pharmacy market.
“We are keeping the momentum going and widening our distribution network in the USA,” Jactel told Proactive.
“We are attracting new distributors all the time. It is a very exciting time.”
TyraTech to launch 10 products in 2014
By Charlotte Kan May 19 2014
Bruno Jactel, chief executive of TyraTech (LON:TYR), tells Proactive Investors the company is launching 10 products this year, including a shampoo that will break the head lice infestation cycle, as well as a non-Deet, non-pesticide mosquito repellant. Tyratech's products are now sold on Amazon.com, drugstore.com and in Walmart, and the company is exploring more distribution channels within the US and Europe.
By Charlotte Kan May 19 2014
Bruno Jactel, chief executive of TyraTech (LON:TYR), tells Proactive Investors the company is launching 10 products this year, including a shampoo that will break the head lice infestation cycle, as well as a non-Deet, non-pesticide mosquito repellant. Tyratech's products are now sold on Amazon.com, drugstore.com and in Walmart, and the company is exploring more distribution channels within the US and Europe.
Antwort auf Beitrag Nr.: 47.012.724 von Jon_Schnee am 20.05.14 11:15:36
Hallo John,
Ich hab 0 Ahnung dazu.
Hast Du bestimmte Erwartungen daran?
Gruß
P.
Zitat von Jon_Schnee: TyraTech to launch 10 products in 2014
Hallo John,
Ich hab 0 Ahnung dazu.
Hast Du bestimmte Erwartungen daran?
Gruß
P.
Antwort auf Beitrag Nr.: 47.053.864 von Popeye82 am 27.05.14 15:30:37Final Results
26 June 2014
TyraTech Inc. (AIM: TYR and TYRU), a life sciences company focusing on nature-derived insect and parasite control products, today announces its final results for the year ended 31 December 2013.
Highlights
Chairman's Comments
Chief Executive Officer's Report and Operational Review
Financial Review
Consolidated Balance Sheet
Consolidated Statement of Operations
Consolidated Statement of Shareholders' Equity
Consolidated Statement of Cash Flows
Notes
http://www.tyratech.com/content/news/archive/2014/26-06-14.a…
26 June 2014
TyraTech Inc. (AIM: TYR and TYRU), a life sciences company focusing on nature-derived insect and parasite control products, today announces its final results for the year ended 31 December 2013.
Highlights
Chairman's Comments
Chief Executive Officer's Report and Operational Review
Financial Review
Consolidated Balance Sheet
Consolidated Statement of Operations
Consolidated Statement of Shareholders' Equity
Consolidated Statement of Cash Flows
Notes
http://www.tyratech.com/content/news/archive/2014/26-06-14.a…
Poweralternatives:Tyratech raises £3.500.000 in oversubscribed placing, ahead of UK launch of its head lice - OB - Jul 24, 2014
- Amy McLellan -
http://oilbarrel.com/news/poweralternatives-tyratech-raises-…
- Amy McLellan -
http://oilbarrel.com/news/poweralternatives-tyratech-raises-…
Vamousse® head lice products coming to Sainsbury's and Tesco in the UK
27 August 2014
TyraTech, Inc. (AIM: TYR and TYRU), a life sciences company focusing on nature-derived insect and parasite control products, is pleased to announce that it has secured product listings for its Vamousse head lice product range, including its Vamousse Treatment mousse and Vamousse Protection shampoo, in Sainsbury's and Tesco stores in the UK. These listings are in addition to those previously announced in respect of Superdrug and Boots and it is anticipated that the first products will appear in UK stores in September.
A UK wide advertising campaign for the Vamousse product line will support the UK expansion. The campaign has been launched to coincide with beginning of the new school year.
In the USA, Vamousse is stocked in over 4000 Walmart stores and is available through online retailers Walmart.com, Amazon.com, drugstore.com, and Walgreens.com. Additionally, the products are now available through extended distribution through one of the major pharmaceutical distributors, McKesson, as well as with independent pharmacy retailers, including Rochester Drug, Lewis Drug and Bartell Drug.
Bruno Jactel, Chief Executive Officer, said: "We are very pleased to have secured, in a short period of time and ahead of the lice season, the inclusion of our Vamousse product range in a number of the major distributors in the pharmacy, health and beauty, and grocery distribution channels in the UK market. In addition, we are extending our distribution network in the USA on-line and through a network of independent pharmacies."
------------
Tesco:
Our operations in the UK are the largest within the Group, with over 3300 stores and over 310,000 colleagues. We have strengthened the foundations of the UK business and we are now accelerating plans to deliver the most compelling offer for customers with sharper prices, improved quality, stronger ranges and better service.
27 August 2014
TyraTech, Inc. (AIM: TYR and TYRU), a life sciences company focusing on nature-derived insect and parasite control products, is pleased to announce that it has secured product listings for its Vamousse head lice product range, including its Vamousse Treatment mousse and Vamousse Protection shampoo, in Sainsbury's and Tesco stores in the UK. These listings are in addition to those previously announced in respect of Superdrug and Boots and it is anticipated that the first products will appear in UK stores in September.
A UK wide advertising campaign for the Vamousse product line will support the UK expansion. The campaign has been launched to coincide with beginning of the new school year.
In the USA, Vamousse is stocked in over 4000 Walmart stores and is available through online retailers Walmart.com, Amazon.com, drugstore.com, and Walgreens.com. Additionally, the products are now available through extended distribution through one of the major pharmaceutical distributors, McKesson, as well as with independent pharmacy retailers, including Rochester Drug, Lewis Drug and Bartell Drug.
Bruno Jactel, Chief Executive Officer, said: "We are very pleased to have secured, in a short period of time and ahead of the lice season, the inclusion of our Vamousse product range in a number of the major distributors in the pharmacy, health and beauty, and grocery distribution channels in the UK market. In addition, we are extending our distribution network in the USA on-line and through a network of independent pharmacies."
------------
Tesco:
Our operations in the UK are the largest within the Group, with over 3300 stores and over 310,000 colleagues. We have strengthened the foundations of the UK business and we are now accelerating plans to deliver the most compelling offer for customers with sharper prices, improved quality, stronger ranges and better service.
so langsam kommt der Kurs dorthin, wo ich mir ein Kauf vorstellen kann.
Abwärtstrend nach ersten Ausbruch ist aber immer noch intakt.
überlege mir ein Kauf bei ca. 6 pence oder wenn eine Trendwende in Sicht ist.
Weiter WatchList Wert
Abwärtstrend nach ersten Ausbruch ist aber immer noch intakt.
überlege mir ein Kauf bei ca. 6 pence oder wenn eine Trendwende in Sicht ist.
Weiter WatchList Wert
Antwort auf Beitrag Nr.: 47.620.218 von Jon_Schnee am 27.08.14 10:29:38Kurs jetzt bei 6.5 pence
Market Cap: -> £16.98 m
Abwärtstend absolut in Takt. derzeit keine Anzeiche von Stärke.
WatchList. 6 pence - ich lasse derzeit die Finger davon
Market Cap: -> £16.98 m
Abwärtstend absolut in Takt. derzeit keine Anzeiche von Stärke.
WatchList. 6 pence - ich lasse derzeit die Finger davon
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 172 | ||
| 120 | ||
| 78 | ||
| 57 | ||
| 56 | ||
| 54 | ||
| 54 | ||
| 53 | ||
| 44 | ||
| 40 |
| Wertpapier | Beiträge | |
|---|---|---|
| 38 | ||
| 31 | ||
| 30 | ||
| 28 | ||
| 27 | ||
| 27 | ||
| 26 | ||
| 23 | ||
| 22 | ||
| 20 |
